Phytogenic zinc oxide nanoparticles in breast cancer therapy: an ethnopharmacological perspective on multi-targeted mechanistic pathways and translational constraints
- 1Department of Rasashastra and Bhaishajya Kalpana (Pharmaceuticals), Amrita School of Ayurveda, Amritapuri, Amrita Vishwa Vidyapeetham , , ,
- 2Department of Ophthalmology, Amrita School of Medicine, Amrita Vishwa Vidyapeetham , ,
- 3Department of Chemistry, Amrita School of Physical Sciences, Amritapuri, Amrita Vishwa Vidyapeetham , , ,
Abstract
Introduction: Breast cancer remains the most frequently diagnosed malignancy and the leading cause of cancer death among women worldwide as of 2026. While conventional interventions face challenges like drug resistance and systemic toxicity, the integration of green nanotechnology with ethnopharmacology offers a biocompatible, sustainable alternative. This review assesses the mechanistic pathways and therapeutic potential of phytogenic zinc oxide nanoparticles (ZnO NPs) synthesized using bioactive secondary metabolites.
Methods: This review combines findings from nine recent studies exploring biogenic ZnO NPs derived from diverse biological sources, including Rhus coriaria L. (Anacardiaceae), Withania somnifera (L.) Dunal (Solanaceae), Zingiber officinale Roscoe (Zingiberaceae). We critically analysed the characterization parameters, synthesis methods and pharmacological efficacy across 3D architectural spheroids, 2D monolayer cultures, and select in vivo models.
Results: The collective data demonstrate that biogenic ZnO-NPs induce potent apoptosis through BAX upregulation, ROS-mediated mitochondrial dysfunction and specific cell cycle arrest. Notable benchmarks include tumour suppression comparable to Tamoxifen in in vivo models using melon-derived extracts and an IC50 of 14.7 μg/mL in 3D MCF-7 spheroids for ginger-mediated NPs.
Discussion: In spite of the promising results, a critical methodological tension exists between limited preclinical validation and innovative synthesis. The pervasive reliance on 2D models often fails to duplicate the dense architectural barriers of solid tumours. Future research must prioritize a realistic translational pathway, shifting from basic in vitro models to rigorous in vivo biodistribution profiling, detailed metabolic tracking, and long-term toxicological assessments against normal mammary epithelial controls (e.g., MCF-10A) to actually establish, rather than merely hypothesize, a definitive, selective therapeutic index and ensure baseline physiological safety.
Related
- Mechanism‐Guided Engineering of Upconversion Nanoparticles for Antibacterial Phototherapy: From Photonic Principles to Translational Nanosystems
- Platelet membrane-coated nanoparticles: Bioengineering principles, quality control, and translational opportunities
- Cell Membrane-Coated Nanoparticles as Biomimetic Drug Delivery Systems: Design, Therapeutic Applications, and Translational Challenges.
- Ethylene-bridged Periodic Mesoporous Organosilica Nanoparticles: controlling architecture through mechanistic investigations
- Repurposing HIV Protease Inhibitors as Antifungal Chemosensitizers Against Multidrug Resistant Candida auris: Promise, Limitations, and Translational Challenges
BibTeX
@article{pillai2026phytogenic,
title = {{Phytogenic zinc oxide nanoparticles in breast cancer therapy: an ethnopharmacological perspective on multi-targeted mechanistic pathways and translational constraints}},
author = {Dhanya Soman Pillai and Ramesh Narve Venkatesha and Amarnath Karavettekudy Ranjit and Zeena Subramonia Pillai},
journal = {Frontiers in pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1883009},
url = {https://europepmc.org/article/PMC/PMC13691436},
note = {CC BY},
}
RIS
TY - JOUR
TI - Phytogenic zinc oxide nanoparticles in breast cancer therapy: an ethnopharmacological perspective on multi-targeted mechanistic pathways and translational constraints
AU - Dhanya Soman Pillai
AU - Ramesh Narve Venkatesha
AU - Amarnath Karavettekudy Ranjit
AU - Zeena Subramonia Pillai
PY - 2026
DA - 2026/10/09
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1883009
UR - https://europepmc.org/article/PMC/PMC13691436
AB - Introduction: Breast cancer remains the most frequently diagnosed malignancy and the leading cause of cancer death among women worldwide as of 2026. While conventional interventions face challenges like drug resistance and systemic toxicity, the integration of green nanotechnology with ethnopharmacology offers a biocompatible, sustainable alternative. This review assesses the mechanistic pathways and therapeutic potential of phytogenic zinc oxide nanoparticles (ZnO NPs) synthesized using bioactive secondary metabolites. Methods: This review combines findings from nine recent studies exploring biogenic ZnO NPs derived from diverse biological sources, including Rhus coriaria L. (Anacardiaceae), Withania somnifera (L.) Dunal (Solanaceae), Zingiber officinale Roscoe (Zingiberaceae). We critically analysed the characterization parameters, synthesis methods and pharmacological efficacy across 3D architectural spheroids, 2D monolayer cultures, and select in vivo models. Results: The collective data demonstrate that biogenic ZnO-NPs induce potent apoptosis through BAX upregulation, ROS-mediated mitochondrial dysfunction and specific cell cycle arrest. Notable benchmarks include tumour suppression comparable to Tamoxifen in in vivo models using melon-derived extracts and an IC50 of 14.7 μg/mL in 3D MCF-7 spheroids for ginger-mediated NPs. Discussion: In spite of the promising results, a critical methodological tension exists between limited preclinical validation and innovative synthesis. The pervasive reliance on 2D models often fails to duplicate the dense architectural barriers of solid tumours. Future research must prioritize a realistic translational pathway, shifting from basic in vitro models to rigorous in vivo biodistribution profiling, detailed metabolic tracking, and long-term toxicological assessments against normal mammary epithelial controls (e.g., MCF-10A) to actually establish, rather than merely hypothesize, a definitive, selective therapeutic index and ensure baseline physiological safety.
SN - 1663-9812
ER -